Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors September 10, 2020
GRAIL Announces Filing of Registration Statement for Proposed Initial Public Offering September 9, 2020
